Aprea Therapeutics, Inc. Common stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
APRE Company Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
APRE Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view APRE Smart Score
Score Breakdown
APRE Company Description
Show More
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of APRE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by APRE's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on APRE's company Twitter account
WallStreetBets
Number of mentions of APRE in WallStreetBets Daily Discussion
APRE News
Recent insights relating to APRE
CNBC Recommendations
Recent picks made for APRE stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in APRE
Corporate Flights
Flights by private jets registered to APRE
Our Analysis